Latigo Biotherapeutics
Develops non-opioid NaV1.8 inhibitors for acute and chronic pain.
$24.23
After-hours close−0.12 (−0.49%)
At close$24.35(−2.60%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions —Insiders 5.87%
Shares outstanding 60.15M · Float 15.45M · 25.7% free float
Institutions13F
No 13F holders on record.
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| James B. Tananbaumincl. Foresite Capital Fund VI LP, Foresite Capital Management VI, LLC +4 more | 14.50% | 9.18M | 13D | Aug 17, 2026 ↗ |
| RA Capital Management, L.P. | 8.40% | 5.30M | 13G | Aug 17, 2026 ↗ |
| Deep Track Capital, LP | 7.03% | 4.45M | 13G | Aug 13, 2026 ↗ |
| AI Biotechnology LLC | 5.00% | 3.19M | 13G | Aug 18, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| James B. Tananbaum | director, 10 percent owner: | 3.41M | 5.68% | Aug 10, 2026 |
| 5AM Ventures VI, L.P. | 10 percent owner | 2.35M | 3.91% | Aug 12, 2026 |
| Sanofi | 10 percent owner | 672.8K | 1.12% | Aug 12, 2026 |
| Nima Farzan | director, officer: President and CEO | 114.5K | 0.19% | Aug 7, 2026 |
2 ten-percent owners hold 3.02M shares by Form 4, outside the officers-and-directors figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 10, 2026 | Foresite Capital Management V, LLC10 percent owner | Purchase | 140,000 | $18.00 | 2,008,024 |
| Aug 10, 2026 | James B. Tananbaumdirector, 10 percent owner: | Purchase | 140,000 | $18.00 | 2,008,024 |
CongressHouse and Senate disclosures
Not reported.